How much funding has Trillium Therapeutics raised?

Trillium Therapeutics has raised $1.0M in total funding, most recently a Venture Round.

Who are Trillium Therapeutics's investors?

Trillium Therapeutics's investors include Pfizer Ventures.

When was Trillium Therapeutics founded?

Trillium Therapeutics was founded in 1996.

Where is Trillium Therapeutics headquartered?

Trillium Therapeutics is headquartered in Toronto, Canada.

What industry is Trillium Therapeutics in?

Trillium Therapeutics operates in Biotech, Healthcare.

How many employees does Trillium Therapeutics have?

Trillium Therapeutics has 51-200 employees.

Trillium Therapeutics

IPO

Public · Toronto, Canada · Founded 1996 · $1.0M raised

Biotech

Healthcare

Headquarters: Toronto
Employees: 51–200
Founded: 1996
Business Model: B2B
Website: trilliumtherapeutics.com

Total Funding: $1.0M
Last Round: $1.0M Venture RoundMay 2011
Rounds: 1
Type: Public

About

Trillium Therapeutics was a clinical-stage immuno-oncology company developing innovative cancer therapies, including fusion proteins targeting CD47, the 'don't eat me' signal used by cancer cells to evade macrophage-mediated killing. Founded in 1996 and publicly traded on NASDAQ and TSX (ticker: TRIL), the company was headquartered in Toronto, Canada with a Cambridge, MA research presence. Pfizer acquired Trillium in 2021 for approximately $2.26 billion to gain access to its two clinical-stage anti-CD47 assets.

Summary

Trillium Therapeutics is a Biotech company based in Toronto, Canada, founded in 1996. It has raised $1.0M in total across 1 round, most recently a $1.0M Venture Round round in May 2011. Investors include Pfizer Ventures.